Self-reported adverse events within the seven days following the Spikevax® (Moderna) vaccination Dulce Guerra-Estévez; Cristina Palomo-Palomo; Alberto Parrado-González; Juila Estaire-Gutiérrez; Miguel Reyes-Malia; M. Mercedes Romero-Alonso;

Inclusion of omalizumab in a trastuzumab desensitization protocol Ester María Barreiro-Fernández; Manuel David Gil-Sierra; María del Pilar Briceño-Casado; Carmen Martínez-Díaz; Esmeralda Ríos-Sánchez;

Reactogenicity of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19 in workers of a tertiary hospital Cristina Palomo-Palomo; Dulce Guerra-Estévez; Alberto Parrado-González; Julia Estaire-Gutiérrez; Miguel Reyes-Malia; M. Mercedes Romero-Alonso;